Our results are consistent with this in the context of PD-L1 status and with previously reported correlation of PD-L1 expression in breast cancer with cytotoxic immune response genes and immune-related pathways and features (e.g., IFN-α, IFN-γ, STAT3, and TNFα) [26, 27]. The gene discussed is IFNG; the disease is breast cancer.